GC
FENC icon

Globeflex Capital’s Fennec Pharmaceuticals FENC Stock Holding History

Globeflex Capital’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-18,343
Closed -$113K – 412
2026
Q1 		$113K Buy
+18,343
New +$142K 0.02% 355

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCA
Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Globeflex Capital's FENC Position: Q2 2026 in Review

Globeflex Capital sold out of Fennec Pharmaceuticals (FENC) in Q2 2026, closing a stake of 18,343 shares — an estimated $113K sold.

Globeflex Capital first reported a position in FENC in Q1 2026 and held it in 1 quarter. The position peaked at $113K in Q1 2026. 105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • Globeflex Capital reported no remaining Fennec Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Globeflex Capital sold 18,343 Fennec Pharmaceuticals shares in Q2 2026, an estimated $113K.
  • Globeflex Capital first reported a position in Fennec Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Globeflex Capital's Fennec Pharmaceuticals position peaked at $113K in Q1 2026.
  • 105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Globeflex Capital's 13F filing for Q2 2026, filed 12 Aug 2026.